Skip to content
value.today

Immunic, Inc.

IMUX
$121 Mmarket cap on Oct 28, 2026+85.9% since Jan 2024
Compare
World rank
#18,073
Revenue
—
For year ending December-2025
Net income
$-97 M
SEC filing
Employees
—

Immunic, Inc. in brief

Immunic, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $121 M on 28 October 2026, which makes it the 18,073rd largest listed company in the world and the 3,422nd largest in the USA on this site. Erik Lundgren is its chief executive. Its shares trade under the symbol IMUX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Immunic, Inc.

Immunic is a Clinical Stage Biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It is having 26 employees as on 2020. The headquarters is in USA.

Immunic, Inc. timeline

3 events, 2004–2019
  1. 2004
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2019
  6. ✎
    Renamed Immunic, Inc.
    Formerly Vital Therapies Inc.

Events of Immunic, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$86 M$171 M$257 M$342 M2020202120222023202420252026

World rank over time

▲ up 911 places since 2020
2020-01-01: #19017#19,01720202021-01-01: #13420#13,42020212022-01-07: #17795#17,79520222022-12-25: #24437#24,43720222023-07-30: #21440#21,44020232024-01-05: #23632#23,63220242026-03-08: #9304#9,30420262026-08-01: #15138#15,13820262026-10-14: #18500#18,50020262026-10-28: #18106#18,1062026

Rank in USA: #3,717 (Jan 2020) · #2,905 (Jan 2021) · #3,633 (Jan 2022) · #4,683 (Dec 2022) · #4,181 (Jul 2023) · #3,936 (Jan 2024) · #1,796 (Mar 2026) · #3,051 (Aug 2026) · #3,452 (Oct 2026) · #3,425 (Oct 2026)

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-12M—FY18Fiscal year ending Dec 2019: revenue —, net income $-35M—FY19Fiscal year ending Dec 2020: revenue —, net income $-44M—FY20Fiscal year ending Dec 2021: revenue —, net income $-93M—FY21Fiscal year ending Dec 2022: revenue —, net income $-120M—FY22Fiscal year ending Dec 2023: revenue —, net income $-94M—FY23Fiscal year ending Dec 2024: revenue —, net income $-101M—FY24Fiscal year ending Dec 2025: revenue —, net income $-97M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-103M$-97M—
Dec 2024——$-98M$-101M—
Dec 2023——$-99M$-94M—
Dec 2022——$-119M$-120M—
Dec 2021——$-92M$-93M—
Dec 2020——$-49M$-44M—
Dec 2019——$-37M$-35M—
Dec 2018——$-12M$-12M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-86M$0M$-86M$-0.62$0.00
Dec 2024$-85M$0M$-85M$-1.00$0.00
Dec 2023$-71M$0M$-71M$-2.11$0.00
Dec 2022$-65M$0M$-65M$-3.78$0.00
Dec 2021$-83M$0M$-83M$-3.93$0.00
Dec 2020$-46M$0M$-46M$-2.81$0.00
Dec 2019$-29M$0M$-29M$-4.52$0.00
Dec 2018$-10M$0M$-10M$-13.63$0.00

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-25M—Dec ’24Three months to Mar 2025: revenue —, net income $-25M—Mar ’25Three months to Jun 2025: revenue —, net income $-27M—Jun ’25Three months to Sep 2025: revenue —, net income $-26M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-19M—Dec ’25Three months to Mar 2026: revenue —, net income $-33M—Mar ’26Three months to Jun 2026: revenue —, net income $-34M—Jun ’26Three months to Sep 2026: revenue —, net income $-42M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-42M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Immunic, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-103 M
Net income
$-97 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$24 M
Total liabilities
$31 M
Total equity
$-7 M

As of December-2025

Top 78 institutional investors in Immunic, Inc.#

As of Sep 30, 2026
78 institutions held 10.9 M shares (about 80.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Immunic, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Aberdeen Group plc1,090,427+266,034 (+32.27%)7.99%$10 MNov 10, 2026
2BVF Inc/il765,2950 (0.00%)5.61%$7 MNov 16, 2026
3Morgan Stanley704,244+680,496 (+2865.49%)5.16%$7 MNov 13, 2026
4Seven Fleet Capital Management LP687,240New5.04%$6 MNov 16, 2026
5Millennium Management LLC681,024-59,323 (-8.01%)4.99%$6 MNov 16, 2026
6Avidity Partners Management LP669,9410 (0.00%)4.91%$6 MNov 16, 2026
7Braidwell LP645,110+100 (+0.02%)4.73%$6 MNov 16, 2026
8Laurion Capital Management LP610,3260 (0.00%)4.47%$6 MOct 30, 2026
9Vanguard Capital Management LLC571,5610 (0.00%)4.19%$5 MNov 13, 2026
10Orbimed Advisors LLC475,804New3.49%$4 MNov 16, 2026
11Woodline Partners LP472,000+472 (+0.10%)3.46%$4 MNov 16, 2026
12Omega Fund Management, LLC430,180New3.15%$4 MNov 16, 2026
13Marshall Wace, LLP359,319+254,503 (+242.81%)2.63%$3 MNov 13, 2026
14Nantahala Capital Management, LLC250,646-250,646 (-50.00%)1.84%$2 MNov 13, 2026
15Propel Bio Management, LLC236,734-88,288 (-27.16%)1.74%$2 MNov 13, 2026
16Jane Street Group, LLC214,163+124,476 (+138.79%)1.57%$2 MNov 12, 2026
17UBS Group AG183,629+7,873 (+4.48%)1.35%$2 MNov 10, 2026
18Ikarian Capital, LLC182,464+115,000 (+170.46%)1.34%$2 MNov 16, 2026
19Geode Capital Management, LLC172,142+1,467 (+0.86%)1.26%$2 MNov 6, 2026
20Qube Research & Technologies Ltd147,577New1.08%$1 MNov 13, 2026
21Adage Capital Partners GP, L.L.C.139,8600 (0.00%)1.02%$1 MNov 16, 2026
22Citadel Advisors LLC129,654+108,034 (+499.69%)0.95%$1 MNov 16, 2026
23BlackRock, Inc.126,222-6,569 (-4.95%)0.93%$1 MNov 13, 2026
24Susquehanna International Group, LLP110,548+19,658 (+21.63%)0.81%$1 MNov 16, 2026
25State Street Corp83,859+22,600 (+36.89%)0.61%$1 MNov 12, 2026
Show all 78: investors 26 to 78
Institutional investors 26 to 78 in Immunic, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Fiduciary Trust Co82,0290 (0.00%)0.60%$1 MNov 13, 2026
27Renaissance Technologies LLC71,330New0.52%$1 MNov 12, 2026
28683 Capital Management, LLC65,000-82,245 (-55.86%)0.48%$1 MNov 16, 2026
29Boothbay Fund Management, LLC46,820+33,763 (+258.58%)0.34%$0 MNov 16, 2026
30Schonfeld Strategic Advisors LLC45,599New0.33%$0 MNov 16, 2026
31Squarepoint Ops LLC42,283New0.31%$0 MNov 9, 2026
32Two Sigma Investments, LP37,671New0.28%$0 MNov 16, 2026
33Engineers Gate Manager LP36,600New0.27%$0 MNov 16, 2026
34Quadrature Capital Ltd31,058-6,728 (-17.81%)0.23%$0 MNov 13, 2026
35Simplify Asset Management Inc.30,7250 (0.00%)0.23%$0 MOct 27, 2026
36Northern Trust Corp30,7200 (0.00%)0.23%$0 MNov 16, 2026
37Birchview Capital, LP21,917New0.16%$0 MNov 13, 2026
38Axq Capital, LP21,009New0.15%$0 MNov 12, 2026
39Graham Capital Management, L.P.19,722New0.14%$0 MNov 16, 2026
40Alps Advisors Inc17,694+3,870 (+27.99%)0.13%$0 MNov 3, 2026
41American Century Companies Inc17,523New0.13%$0 MNov 12, 2026
42LPL Financial LLC17,012-429 (-2.46%)0.12%$0 MNov 6, 2026
43Catalyst Funds Management Pty Ltd16,339New0.12%$0 MNov 12, 2026
44XTX Topco Ltd15,240New0.11%$0 MNov 16, 2026
45Spark Investment Management LLC11,600New0.09%$0 MNov 13, 2026
46MML Investors Services, LLC11,487-3,175 (-21.65%)0.08%$0 MNov 13, 2026
47Point72 Asset Management, L.P.10,8060 (0.00%)0.08%$0 MNov 16, 2026
48Prelude Capital Management, LLC10,779New0.08%$0 MNov 16, 2026
49Bank Of America Corp /de/10,472New0.08%$0 MNov 16, 2026
50Strategies Wealth Advisors, LLC10,0000 (0.00%)0.07%$0 MNov 13, 2026
51China Universal Asset Management Co., Ltd.7,800+1,400 (+21.88%)0.06%$0 MOct 28, 2026
52Simplex Trading, LLC6,667New0.05%$0 MNov 4, 2026
53Vanguard Global Advisers, LLC6,160+2,974 (+93.35%)0.05%$0 MNov 13, 2026
54Walleye Capital LLC5,008New0.04%$0 MNov 13, 2026
55Barclays PLC4,025+3,531 (+714.78%)0.03%$0 MNov 6, 2026
56Acadian Asset Management LLC3,549New0.03%$0 MNov 9, 2026
57Royal Bank Of Canada2,470+1,470 (+147.00%)0.02%$0 MNov 16, 2026
58Tower Research Capital LLC (TRC)2,134New0.02%$0 MNov 16, 2026
59Citigroup Inc1,517-3,052 (-66.80%)0.01%$0 MNov 4, 2026
60Providence Capital Advisors, LLC6820 (0.00%)0.01%$0 MNov 13, 2026
61SBI Securities Co., Ltd.515+142 (+38.07%)0.00%$0 MOct 22, 2026
62Pinnacle Financial Group, Inc.440—0.00%$0 MNov 16, 2026
63Jones Financial Companies Lllp355New0.00%$0 MNov 13, 2026
64FMR LLC337+209 (+163.28%)0.00%$0 MNov 10, 2026
65Northwestern Mutual Wealth Management Co1500 (0.00%)0.00%$0 MNov 13, 2026
66Rockefeller Capital Management L.P.1000 (0.00%)0.00%$0 MNov 13, 2026
67Allworth Financial LP840 (0.00%)0.00%$0 MNov 17, 2026
68Nova Financial LLC80-100 (-55.56%)0.00%$0 MNov 4, 2026
69Rialto Wealth Management, LLC49New0.00%$0 MNov 16, 2026
70Cassaday & Co Wealth Management LLC40New0.00%$0 MOct 27, 2026
71Jpmorgan Chase & Co380 (0.00%)0.00%$0 MNov 12, 2026
72Caitong International Asset Management Co., Ltd18+16 (+800.00%)0.00%$0 MOct 29, 2026
73Caldwell Sutter Capital, Inc.100 (0.00%)0.00%$0 MNov 9, 2026
74Aster Capital Management (DIFC) Ltd3New0.00%$0 MNov 12, 2026
75Wells Fargo & Company/mn2-85 (-97.70%)0.00%$0 MNov 16, 2026
76Danske Bank A/s20 (0.00%)0.00%$0 MNov 9, 2026
77Smartleaf Asset Management LLC2New0.00%$0 MNov 10, 2026
78Robinhood Markets, Inc.1—0.00%$0 MNov 18, 2026

Mutual funds holding Immunic, Inc.#

21 funds hold shares worth $24 M (about 11.7% of the company). Since their previous reports 14 added shares and 5 sold, buying $1 M net.
Mutual funds holding Immunic, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 abrdn Healthcare Investorsabrdn Inc.473,877$7 M3.5%0.53%−0.0%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.399,088$6 M2.9%<0.01%+8.9%Jun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.302,891$5 M2.2%0.68%−0.0%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.159,248$2 M1.2%<0.01%+17%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC63,010$1 M0.46%<0.01%−2.1%May 31, 2026
🇺🇸 abrdn World Healthcare Fundabrdn Inc.47,625$1 M0.35%0.13%−0.0%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors46,243$1 M0.34%0.05%+52%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC29,253$0 M0.21%<0.01%−0.0%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC17,808$0 M0.13%<0.01%+14%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC9,839$0 M0.07%<0.01%+152%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.8,500$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC8,037$0 M0.06%<0.01%+30%Jul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.6,993$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,232$0 M0.05%<0.01%+46%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC5,154$0 M0.04%<0.01%+23%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,121$0 M0.02%0.02%+47%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,207$0 M0.02%<0.01%+18%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,556$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC866$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC297$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC277$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 21 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Immunic, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
$247 K$0Feb 2024: bought $18 K (1 trades), sold $0 (0 trades)Feb 24Nov 2024: bought $100 K (1 trades), sold $0 (0 trades)NovJun 2025: bought $247 K (7 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Immunic, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Duane NashExecutive Chairman, DirectorBuy+20,000$0.830$17 K36,032Form 4
filed Jason TardioPresident and COOBuyamended+12,512$0.790$10 K12,512Form 4/A
filed Jason TardioPresident and COOBuy+12,512$0.790$10 K12,512Form 4
filed Joerg NeermannDirectorBuy+30,000$0.760$23 K200,000Form 4
filed Daniel VittCEO and Director, DirectorBuyamended+15,000$0.770$12 K29,000Form 4/A
filed Daniel VittCEO and Director, DirectorBuy+15,000$0.770$12 K29,000Form 4
filed Joerg NeermannDirectorBuy+70,000$0.770$54 K170,000Form 4
filed Richard Alan RudickDirectorBuy+143,075$0.700$100 K230,375Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Immunic, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.0 M
16.2% of shares · 5.73 days to cover
Dividend per share, Q1 2026
$0.000
— on a year earlier
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-40 reverse split

Immunic, Inc. dividends per share by quarter
Dividend, quarterPer share
Q1 2026$0.000
Q1 2025$0.000
Q1 2024$0.000
Q1 2023$0.000
Q1 2022$0.000
Q1 2021$0.000
Q1 2020$0.000

Trading halts

  • 2026-04-24 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 3,875 shares at $7.61
  • : 465 shares at $6.97
  • : 13 shares at $6.66
  • : 13 shares at $6.89
  • : 557 shares at $7.95

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Immunic, Inc. scorecard#

Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-71.1%Free cash flow is -71.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.62 vs -1.00Diluted EPS -0.62 in fiscal 2025 against -1.00 the year before (report's currency).
    • ✗Net income higher than five years earlier-$97 M-$97 M in fiscal 2025 against -$44 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$97 MNet income -$97 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.75 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 3
    • ✗Pays a dividendNoNo dividends in fiscal 2025.
    • ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year55.4%Diluted shares up 55.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Immunic, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Immunic, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development828083716139239.6r3930
General and administrative211816151310152.4r1311
Operating expenses103989911992493712r5341
Operating income−103−98−99−119−92−49−37−12r−53−41
Interest and finance income1.03.43.11.00.10.10.10.50.70.3
Provision for credit losses0.50.2————————
Other non-operating income (expense)6.1−2.55.6−0.9−1.35.02.10.5r0.60.3
Income before tax———————−41−52−41
Income tax0—————————
Net income including minority interests————————−52−41
Net income attributable to shareholders−97−101−94−120−93−44−35−12r−52−41
Earnings per share, basic-0.62-1.00-2.11-3.78-3.93-2.81-4.52-13.63r-1.31-1.31
Earnings per share, diluted-0.62-1.00-2.11-3.78-3.93-2.81-4.52-13.63r-1.31-1.31
Shares, weighted average (basic)15610044322416————
Shares, weighted average (diluted)156100443224167.70.8r4031
Dividends per share0.000.000.000.000.000.000.000.00——
Balance sheet
Cash and cash equivalents153647107871272913r5760
Other current assets0.8r1.1r1.1r1.21.11.20.8r0.1r1.21.5
Current assets2339531261051343213r5861
Property, plant and equipment0.60.50.50.30.20.20.10.0r2.22.5
Right-of-use (leased) assets0.61.01.31.60.90.90.6———
Goodwill———03333330——
Total assets2441541281391686613r6064
Accounts payable107.85.14.33.73.72.41.4r1.00.8
Current liabilities31222513118.47.11.9r105.5
Lease liabilities (non-current)0.10.30.61.00.60.70.50.00.1—
Non-current liabilities0.10.30.61.00.60.70.50r0.10.1
Total liabilities31222514129.17.61.9——
Retained earnings−609−511−411−317−197−104−60−25r−296−244
Shareholders' equity−6.7182911412715958−26r−13r58
Total liabilities and equity2441541281391686613r6064
Shares outstanding16r9045392621110.8r4232
Cash-flow statement
Depreciation and amortization0.20.10.10.10.10.00.10.0r1.01.8
Share-based compensation8.98.57.17.95.92.76.50r5.54.7
Cash from operating activities−86−85−71−65−83−46−29−9.7r−40−36
Capital expenditure−0.2−0.3−0.3−0.1−0.1−0.1−0.1−0.0r−0.7−0.6
Intangible assets bought—————0−0.1———
Cash from investing activities−0.2−0.39.5−9.7−0.1−0.111−0.0r−0.7−0.0
Shares issued00.20.9———019r3812
Cash from financing activities66751.096431443519r3812
Exchange-rate effect on cash0.2−0.50.3−1.0−0.1−0.1−0.6−0.9——
Change in cash−20−11−6020−4198168.6r−3.1−23
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Immunic, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Immunic, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇩🇪 Germany1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Immunic, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 13 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5

Immunic, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officersResults announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Directors and officersShareholder vote8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 11, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Immunic, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2026$200 MPrivate placement after listing$50 to $250 million43equity, optionsSEC
Jan 2024$80 MPrivate placement after listing$50 to $250 million19equity, optionsSEC
Oct 2022$60 MPrivate placement after listing$50 to $250 million14equity, optionsSEC
Jan 2014$14 MNo. 5$10 to $50 million37equitySEC
Feb 2013$32 MNo. 4$10 to $50 million62equitySEC
Sep 2012$86 MNo. 3$50 to $250 million40equity, optionsSEC
May 2012$3 MNo. 2$2 to $10 million1debt, optionsSEC
May 2011$23 MNo. 1$10 to $50 million51equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Immunic, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
117
2015–2018
Latest
85 people
2018-09-13
Immunic, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2018········85···85
2015·······32····32
Immunic, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
85 peopleRestructuring planSEC 8-K“(the “Company”) began notifying approximately 85 employees whose employment will be terminated on September 14, 2018.”Filing
32 peopleRestructuring planSEC 8-K“The plan is expected to include a workforce reduction in force of 32 people.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Immunic, Inc. compares in Biotechnology

  • Market cap$121 M · higher than 39% of 726
  • FCF yield-71.1% · higher than 16% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Immunic, Inc.🇺🇸$121 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Immunic, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Immunic, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Immunic, Inc.? Suggest a correction